| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥3.20B | +89.6% |
| Gross profit | ¥1.50B | — |
| Operating income | ¥1.31B | — |
| Net income | ¥1.11B | +1206.4% |
| Gross margin | 47.0% | Net margin 34.7% |
| Revenue Q/Q | +61.8% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥1.70B | 53.0% |
| R&D | ¥0.02B | 0.6% |
| SG&A | ¥0.15B | 4.7% |
| Tax & other | ¥0.20B | 6.2% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
中来股份 ・ 菲利华 ・ ST迪瑞 ・ 天和防务 ・ 飞凯材料 ・ 天利科技 ・ 劲拓股份 ・ 花园生物 ・ 宝色股份 ・ 汉宇集团 ・ 博济医药 ・ 科隆股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies